Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AMN Healthcare Services, Inc. stock logo
AMN
AMN Healthcare Services
$21.07
-0.4%
$20.83
$17.45
$70.07
$806.67M0.16912,515 shs301,141 shs
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$103.06
+8.1%
$91.51
$73.04
$121.90
$6.66B0.83787,375 shs1.40 million shs
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$12.68
-0.2%
$16.23
$11.60
$32.66
$985.39M1.271.04 million shs980,705 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$269.93
-0.3%
$308.27
$200.63
$377.46
$5.99B-0.91381,581 shs371,591 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AMN Healthcare Services, Inc. stock logo
AMN
AMN Healthcare Services
-0.09%-2.81%+4.62%-16.82%-61.02%
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
+8.14%+2.71%+16.48%+6.72%+2.48%
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
-0.16%+0.16%-26.92%-45.37%-57.16%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-0.35%-1.25%-20.80%-20.90%+21.31%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AMN Healthcare Services, Inc. stock logo
AMN
AMN Healthcare Services
4.431 of 5 stars
3.12.00.84.33.41.71.9
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
1.8222 of 5 stars
3.41.00.00.02.90.80.6
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
4.5733 of 5 stars
3.91.00.04.03.11.72.5
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
4.2406 of 5 stars
3.51.00.04.62.54.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AMN Healthcare Services, Inc. stock logo
AMN
AMN Healthcare Services
2.25
Hold$32.0852.27% Upside
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
2.83
Moderate Buy$126.5622.80% Upside
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
1.78
Reduce$18.6346.88% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.90
Moderate Buy$416.3354.24% Upside

Current Analyst Ratings Breakdown

Latest AMN, BPMC, MDGL, and IART Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
AMN Healthcare Services, Inc. stock logo
AMN
AMN Healthcare Services
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$30.00 ➝ $25.50
5/9/2025
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$35.00 ➝ $25.00
5/6/2025
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$25.00 ➝ $13.00
5/6/2025
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$24.00 ➝ $12.00
5/2/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$135.00 ➝ $135.00
5/2/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$441.00 ➝ $458.00
5/2/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$422.00 ➝ $460.00
5/2/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$394.00 ➝ $420.00
5/1/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$128.00
4/28/2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$133.00 ➝ $130.00
4/24/2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$443.00 ➝ $443.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AMN Healthcare Services, Inc. stock logo
AMN
AMN Healthcare Services
$2.85B0.28$5.90 per share3.57$18.56 per share1.14
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$562.12M11.84N/AN/A$4.67 per share22.07
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$1.62B0.61$2.78 per share4.56$20.31 per share0.62
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$317.38M18.88N/AN/A$20.53 per share13.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AMN Healthcare Services, Inc. stock logo
AMN
AMN Healthcare Services
-$146.98M-$4.33N/A8.71N/A-4.93%15.22%4.72%8/14/2025 (Estimated)
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$67.09M-$2.47N/A158.55N/A-13.19%-77.49%-20.84%8/7/2025 (Estimated)
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$67.74M-$0.38N/A5.070.73-0.42%12.35%4.82%8/4/2025 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$373.63M-$18.05N/AN/AN/AN/A-71.78%-53.25%8/6/2025 (Estimated)

Latest AMN, BPMC, MDGL, and IART Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
AMN Healthcare Services, Inc. stock logo
AMN
AMN Healthcare Services
$0.19$0.45+$0.26-$0.03$670.08 million$689.53 million
5/5/2025Q1 2025
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
$0.43$0.41-$0.02-$0.33$381.17 million$382.65 million
5/1/2025Q1 2025
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million
5/1/2025Q1 2025
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$3.62-$3.32+$0.30-$3.32$112.79 million$137.25 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AMN Healthcare Services, Inc. stock logo
AMN
AMN Healthcare Services
$1.205.70%N/AN/A N/A
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AMN Healthcare Services, Inc. stock logo
AMN
AMN Healthcare Services
1.49
1.09
1.18
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
1.15
2.85
2.80
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
0.79
1.20
0.73
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.15
5.98
5.93

Institutional Ownership

CompanyInstitutional Ownership
AMN Healthcare Services, Inc. stock logo
AMN
AMN Healthcare Services
99.23%
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/A
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
84.78%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
AMN Healthcare Services, Inc. stock logo
AMN
AMN Healthcare Services
4,23038.29 million37.72 millionOptionable
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
64064.58 million61.22 millionOptionable
Integra LifeSciences Holdings Co. stock logo
IART
Integra LifeSciences
3,72077.71 million74.77 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9022.20 million16.84 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMN Healthcare Services stock logo

AMN Healthcare Services NYSE:AMN

$21.07 -0.08 (-0.38%)
Closing price 05/29/2025 03:59 PM Eastern
Extended Trading
$21.09 +0.02 (+0.09%)
As of 05/29/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.

Blueprint Medicines stock logo

Blueprint Medicines NASDAQ:BPMC

$103.06 +7.76 (+8.14%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$102.40 -0.66 (-0.64%)
As of 05/29/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Integra LifeSciences stock logo

Integra LifeSciences NASDAQ:IART

$12.68 -0.02 (-0.16%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$12.60 -0.08 (-0.67%)
As of 05/29/2025 07:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$269.93 -0.94 (-0.35%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$270.30 +0.37 (+0.14%)
As of 05/29/2025 04:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.